Brokerage firm Nomura has reiterated its 'Buy' ratings on Star Health and Niva Bupa, citing optimism about ongoing regulatory reforms in the health insurance sector. These initiatives aim to stabilize loss ratios as the industry manages annual medical inflation of 12-14%. Investors are tracking how standardized treatment rates and new claim exchanges will impact long-term profitability for these insurers.
Brokerage firm Nomura has maintained its 'Buy' ratings on Star Health and Allied Insurance and Niva Bupa Health Insurance, pointing to a more stable outlook for the Indian health insurance sector. The brokerage believes that ongoing regulatory changes could simplify operations and make financial performance for these companies more predictable.
The health insurance industry has historically faced significant volatility due to unpredictable claim costs. Nomura suggests that government-led initiatives, such as the creation of a national health claim exchange and the standardization of hospital treatment protocols, are key steps toward reducing this uncertainty. By creating a more transparent system for pricing, regulators hope to balance the need for affordable patient access with the financial sustainability of insurance companies.
For investors, the primary concern in this sector has been medical inflation, which is currently estimated between 12% and 14% each year. This means the cost of medical services is rising faster than general price levels. If these costs climb too quickly, insurers must raise premiums to cover claims, which can be difficult to manage. The proposed regulatory reforms aim to address this by establishing benchmark rates for procedures, which would help insurers better predict their payouts and manage their loss ratios—a critical measure of how much money an insurer spends on claims relative to the premiums it collects.
Both Star Health and Niva Bupa are major standalone health insurers that have been navigating this competitive environment. Niva Bupa has shown recent financial growth, reporting a 93% year-on-year increase in profit after tax as of July 2026, and maintaining a solvency ratio of roughly 2.49 times. These figures provide a look at how the company has been managing its capital and expansion efforts prior to the full implementation of the new regulatory framework.
However, risks remain for the industry. The proposed regulatory changes are still in the development phase, and the transition to a new system could create uncertainty in pricing models and distribution. Additionally, intense competition in the standalone health insurance market continues to put pressure on profit margins. If premium repricing does not keep pace with the rising costs of medical care, insurers could face pressure on their underwriting performance.
Moving forward, the implementation timeline for the proposed reforms will be the most important monitorable for shareholders. Investors will likely look for updates from the specialized working committees tasked with streamlining the sector and watch for any impact these changes have on quarterly loss ratios and pricing power.